Compare OIS & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OIS | RLMD |
|---|---|---|
| Founded | 1995 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.6M | 661.9M |
| IPO Year | 2000 | 2012 |
| Metric | OIS | RLMD |
|---|---|---|
| Price | $8.08 | $6.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $14.00 | $12.40 |
| AVG Volume (30 Days) | 744.0K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $1,088,133,000.00 | $13,070.00 |
| Revenue This Year | $3.12 | N/A |
| Revenue Next Year | $5.89 | N/A |
| P/E Ratio | $397.50 | ★ N/A |
| Revenue Growth | 62.26 | ★ 154.83 |
| 52 Week Low | $4.75 | $0.55 |
| 52 Week High | $14.50 | $8.00 |
| Indicator | OIS | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 37.21 | 47.20 |
| Support Level | $7.77 | $6.17 |
| Resistance Level | $8.71 | $7.46 |
| Average True Range (ATR) | 0.27 | 0.45 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 39.83 | 60.47 |
Oil States International Inc is a provider of manufactured products and services to customers in the energy, military and industrial sectors. The company operates through three business segments - Offshore Manufactured Products, Completion and Production Services and Downhole Technologies. Its customers include many national oil and natural gas companies, and independent oil and natural gas companies, offshore drilling companies and other oilfield service, defense and industrial companies.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.